Intrahepatic cholestasis of pregnancy (ICP) is a disease of the third trimester of pregnancy involving pruritus and elevated bile acid levels. Once thought to be benign for both mother and fetus, ICP has been associated with maternal jaundice and increased rates of fetal morbidity and mortality. However ursodeoxycholic acid (UDCA) has proved to be effective and safe in patients with ICP, attenuating pruritus and correcting some biochemical abnormalities in the mothers. The fetal outcome has also been suggested to improve in patients receiving UDCA. This review intends to verify the validity of the UDCA uses to reduce fetal morbidity and mortality. For this a detailed search of the medical bibliography was done in different data bases. Applying different criteria, 4 articles were finally selected and this constitutes the base of our review. Based on the research, one concludes that there is not enough evidence in the literature to support the use of UDCA to improve perinatal outcome. Although some studies propose an improved fetal outcome in patient using UDCA, these do not count with the validity and the statistical power to modify the present management of ICP.
|Translated title of the contribution||Does the use of ursodeoxycholic acid improves prenatal prognosis in pregnant women with intrahepatic cholestasis of pregnancy?|
|Number of pages||6|
|Journal||Revista Chilena de Obstetricia y Ginecologia|
|State||Published - 2007|